Criteria to qualify for study: Drug used in study:
  • Documentation of CD19 expression; ECOG of 0 or 1

ALL 06

An Open-Label, Multi-Centre, Phase lb/ll study evaluating the safety and efficacy of Auto1, A CAR-T Cell treatment targeting CD19 in adult patients with relapsed of refractory B Cell Acute Lymphoblastic Leukemia.

ALL 06 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • ECOG <1; relapsed or refractory NHL, ALL, or i NHL; at least 2 prior lines

HR 69

A phase 1 study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell therapy, in subjects with B-Cell Malignancies.

HR 69 Clinical Trial